2013 Year in Review for OncoSec

We’ve had a busy year at OncoSec. From our ongoing clinical trials to the formation of our melanoma board, research agreement with Old Dominion University and in between, the last year has moved us deeper into cancer research and engaging with patient communities. As we have only a matter of days left in 2013, we would like to look back at this year in review. Here is a selection of some of our activities this year:

Continue reading “2013 Year in Review for OncoSec”

Smart Patients and OncoSec Medical

Smart Patients is an online platform that connects cancer patients and caregivers, allowing for an exchange of knowledge and support. Co-founded by Gilles Frydman and Roni Zeiger, MD – Google’s former chief health strategist – Smart Patients is a platform where users can share stories about their personal experiences, talk about the current leading research in the field, as well as access a library of clinical trials. By combining a message board community and archive of clinical trials, cancer affected patients, friends and family have an invaluable resource in their own home.

Continue reading “Smart Patients and OncoSec Medical”

OncoSec Collaborates with Smart Patients to Form New Online Community for Patients Co-Founded by Former Chief Health Strategist of Google


SAN DIEGO – April 18, 2013 – OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, is one of the first to partner with Smart Patients: a new online community where patients with life-threatening conditions who are looking for or participating in clinical trials can share their feedback and experiences. Google’s former Chief Health Strategist, Roni Zeiger, will be speaking at the TEDMED conference in Washington, D.C. today to unveil the new website.

OncoSec is working with Smart Patients to create a community for Merkel cell carcinoma (MCC) patients. MCC is an extremely rare and aggressive form of skin cancer that currently has no approved therapies. OncoSec is conducting the only active Phase II immunotherapy trial that is focused specifically on the disease. The Smart Patients partnership will provide valuable insight from patients to help improve clinical trial design and enable better collaboration with patients.

“We’re excited to be working with Dr. Zeiger, and to be a part of creating this valuable resource for the Merkel cell community,” said OncoSec’s CEO, Punit Dhillon. “One of the most frightening parts of being diagnosed with a rare disease like MCC is a lack of information about the condition and treatment options. Smart Patients is providing an important resource to help patients connect and learn from each other.”

Roni Zeiger, co-founder and CEO of Smart Patients, noted, “Together with OncoSec, we will be able to gain a better understanding of MCC from a patient perspective, and help design more patient-centered trials that will make scientific breakthroughs for this disease available sooner.”

About Smart Patients

Smart Patients is an online community for cancer patients and caregivers. The community includes a clinical trial search engine that presents trial data from in a patient-friendly format. The community platform has been in private beta testing since January 2013 and is now open to all cancer patients and caregivers. To learn more, please visit us at